口服普萘洛尔对增殖期血管瘤患儿尿液bFGF、MMP-2和MMP-9表达水平的影响

doi:10.19439/j.sjos.2022.04.012

上海口腔医学 ›› 2022, Vol. 31 ›› Issue (4): 400-405.doi: 10.19439/j.sjos.2022.04.012

口服普萘洛尔对增殖期血管瘤患儿尿液bFGF、MMP-2和MMP-9表达水平的影响

袁尉力¹, 王绪凯²

1.中国医科大学附属第四医院口腔科,辽宁沈阳 110032;
2.中国医科大学口腔医学院口腔颌面外科,辽宁省口腔医学研究所口腔颌面外科研究室,辽宁沈阳 110002

收稿日期:2021-09-29 修回日期:2021-11-20 出版日期:2022-08-25 发布日期:2022-08-30
通讯作者: 王绪凯,Email：wangxukai757892@sina.com
作者简介:袁尉力(1982-),男,博士,副主任医师,E-mail：ywlcmu@163.com
基金资助:
辽宁省教育厅课题（2009A747）

Effects of oral propranolol on urine bFGF, MMP-2, MMP-9 expression in children with proliferative infantile hemangioma

YUAN Wei-li¹, WANG Xu-kai²

1. Department of Stomatology, The Fourth Affiliated Hospital, China Medical University. Shenyang 110032;
2. Department of Oral and Maxillofacial Surgery, School of Stomatology, China Medical University, Liaoning Institute of Dental Research. Shenyang 110002, Liaoning Province, China

Received:2021-09-29 Revised:2021-11-20 Online:2022-08-25 Published:2022-08-30

摘要/Abstract

摘要： 目的: 探讨增殖期婴幼儿血管瘤患儿口服普萘洛尔前、后2个月尿液中bFGF、MMP-2和MMP-9的表达水平变化,初步探索普萘洛尔治疗婴幼儿血管瘤的作用机制。方法: 收集2018年6月—2019年6月在中国医科大学附属口腔医院口腔颌面外科病区住院的增殖期血管瘤患儿34例。分别在患儿口服普萘洛尔前、后2个月留取清晨无菌中段尿10 mL,另外收集21例正常婴幼儿（年龄<12个月）的清晨无菌中段尿10 mL作为对照组,采用酶联免疫吸附法检测3组尿液样本中bFGF的表达水平,采用明胶酶谱法检测3组尿液样本中MMP-2和MMP-9的表达水平。采用SPSS 22.0软件包对数据进行统计学分析。结果: 口服普萘洛尔后2个月,患儿尿液中bFGF的表达水平显著低于治疗前（P<0.01）,但仍显著高于对照组（P<0.05）;MMP-2和MMP-9的表达水平显著低于治疗前（P<0.01）,但仍高于对照组（P<0.05）。结论: 普萘洛尔治疗增殖期血管瘤患儿的作用机制之一,可能是通过抑制患儿体内bFGF、MMP-2和MMP-9的表达水平,进而抑制血管瘤中血管内皮细胞的增殖与血管生成,达到治疗血管瘤的目的。检测尿液中bFGF、MMP-2和MMP-9的表达水平,可作为患儿口服普萘洛尔用药过程中的评价指标。

关键词: 普萘洛尔, 婴幼儿血管瘤, 增殖期, 尿液, 碱性成纤维细胞生长因子, 基质金属蛋白酶2, 基质金属蛋白酶9

Abstract: PURPOSE: To investigate the effect of propranolol on urine bFGF, MMP-2, MMP-9 expression of children with proliferative infantile hemangioma(IH), so as to clarify the mechanism of propranolol in treating IH. METHODS: From June 2018 to June 2019, thirty-four children with proliferative IH were treated with oral propranolol. In addition, twenty-one normal children (age <12 months) were chosen as the control group. 10 mL of sterile morning urine were collected before and 2 months after oral administration of propranolol in infants with IH. All blood samples were placed in ordinary disinfection test tubes, centrifuged at 1 000 r/min for 10 min, the supernatant of urine was collected and stored separately. The urine samples of normal control group were processed in the same way. The expression levels of bFGF in the urine of children with proliferative IH before and 2 months after oral administration of propranolol and in the normal control group were detected by enzyme-linked immunosorbent assay (ELISA). The expression levels of MMP-2 and MMP-9 in the urine of children with proliferative IH before and 2 months after treatment and in the control group were detected by gelatin zymography. SPSS 22.0 software package was used to analyze the data. RESULTS: Two months after oral propranolol treatment, the concentration of bFGF in urine was significantly lower than that before treatment (P<0.01), but still significantly higher than that in the control group (P<0.05). The expression levels of MMP-2 and MMP-9 were significantly lower than those before treatment(P<0.01), but still higher than those in the control group (P<0.05). CONCLUSIONS: One of the mechanisms of propranolol in the treatment of children with proliferative IH may be through inhibiting the expression levels of bFGF, MMP-2 and MMP-9, and then inhibiting the proliferation and angiogenesis of vascular endothelial cells in IH, so as to achieve the effect of treating hemangioma. The detection of the expression levels of bFGF, MMP-2 and MMP-9 in urine can be used as the index for oral propranolol treatment of children with proliferative IH.

Key words: Propranolol, Infantile hemangioma, Proliferative phase, Urine, Basic fibroblast growth factor, Matrix metalloproteinase 2, Matrix metalloproteinase 9

中图分类号:

R739.8

袁尉力, 王绪凯. 口服普萘洛尔对增殖期血管瘤患儿尿液bFGF、MMP-2和MMP-9表达水平的影响[J]. 上海口腔医学, 2022, 31(4): 400-405.

YUAN Wei-li, WANG Xu-kai. Effects of oral propranolol on urine bFGF, MMP-2, MMP-9 expression in children with proliferative infantile hemangioma[J]. Shanghai Journal of Stomatology, 2022, 31(4): 400-405.

参考文献

[1] Haggstrom AN, Drolet BA, Baselga E, et al.Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics[J]. J Pediatr, 2007, 150(3): 291-294.
[2] Haggstrom AN, Lammer EJ, Schneider RA, et al.Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development[J]. Pediatrics, 2006, 117(3): 698-703.
[3] 郑家伟, 张凌, 陈正岗. 婴幼儿血管瘤的诊断与治疗[J]. 中国口腔颌面外科杂志, 2015, 13(4): 289-296.
[4] 郑家伟, 张凌. 婴幼儿血管瘤治疗理念与方法的转变[J].中华口腔医学研究杂志(电子版), 2015, 9(2): 91-94.
[5] Satterfield KR, Chambers CB.Current treatment and management of infantile hemangiomas[J]. Surv Ophthalmol, 2019, 64(5): 608-618.
[6] Soliman YS, Khachemoune A.Infantile hemangiomas: our current understanding and treatment options[J]. Dermatol Online J, 2018, 24(9): 1-14.
[7] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008, 358(24): 2649-2651.
[8] 刘学健, 秦中平, 邰茂众, 等. 普萘洛尔治疗婴幼儿腮腺血管瘤的临床观察[J]. 中华口腔医学杂志, 2010, 45(5): 292-294.
[9] Prey S, Voisard JJ, Delarue A, et al.Safety of propranolol therapy for severe infantile hemangioma[J]. JAMA, 2016, 315(4): 413-415.
[10] 郑家伟, 王绪凯, 秦中平, 等. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识[J]. 上海口腔医学, 2016, 25(3): 257-260.
[11] Chang J, Most D, Bresnick S, et al.Proliferative haemangiomas: analysis of cytokine gene expression and angiogenesis[J]. Plast Reconstr Surg, 1999, 103(1): 1-9.
[12] Folkman J.Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis[J]. N Engl J Med, 1995, 333(26): 1757-1763.
[13] 张莉, 陈乾, 李丹, 等. 血VEGF和尿bFGF在血管性疾病鉴别诊断中的应用价值[J]. 中华医学杂志, 2011, 91(16): 1092-1095.
[14] Yang XJ, Jiang YH, Zheng JW, et al.The role of serum basic fibroblast growth factor, estradiol and urine basic fibroblast growth factor in differentiating infantile haemangiomas from vascular malformations[J]. Phlebology, 2011, 26(5): 191-196.
[15] Zhong S, Yang G, Xia C, et al.Expression of matrix metalloproteinase and its tissue inhibitor in haemangioma[J]. J Huazhong Univ Sci Technolog Med Sci, 2009, 29(5): 614-619.
[16] 李琳, 王胜春, 于建斌.MMP 9、VEGF在婴幼儿血管瘤中的表达及意义[J]. 中国实用医药, 2015, 10(12): 66-67.
[17] Marler JJ, Fishman SJ, Kilroy SM, et al.Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies[J]. Pediatrics, 2005, 116(1): 38-45.
[18] Waner M, Suen JY. Hemangiomas and vascular malformations of the head and neck[M]. New York: Wiley-Liss Inc., 1999:3, 57-58, 93-169.
[19] Tan ST, Itinteang T, Leadbitter P.Low-dose propranolol for infantile haemangioma[J]. J Plast Reconstr Aesthet Surg, 2011, 64(3): 292-299.
[20] 胡强, 王琦, 商爱农, 等. 皮肤血管瘤中MC与bFGF关系的实验研究[J]. 中华整形外科杂志, 2004, 20(1): 69-71.
[21] 董长宪, 李恭才. 碱性纤维母细胞生长因子在血管瘤及血管畸形中的表达[J]. 中华小儿外科杂志, 1997, 18(6): 322-324.
[22] Visse R, Nagase H.Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry[J]. Circ Res, 2003, 92(8): 827-839.
[23] Annabi B, Lachambre MP, Plouffe K, et al.Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion[J]. Pharmacol Res, 2009, 60(5): 438-445.
[24] Jadhav U, Chigurupati S, Lakka SS, et al.Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells[J]. Int J Oncol, 2004, 25(5): 1407-1414.
[25] Storch CH, Hoeger PH.Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action[J]. Br J Dermatol, 2010, 163(2): 269-274.
[26] Mitropoulos D, Kyroudi-Voulgari A, Stratigea F, et al.Beta-adrenergic receptor blockade and prostate peptide growth factor expression in the rat[J]. Immunopharmacol Immunotoxicol, 2010, 32(1): 105-109.
[27] Kozawa O, Niwa M, Matsuno H, et al.Stimulatory effect of basic fibroblast growth factor on induction of heat shock protein 27 in osteoblasts: role of protein kinase C[J]. Arch Biochem Biophys, 2001, 388(2): 237-242.
[28] Thaker PH, Han LY, Kamat AA, et al.Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma[J]. Nat Med, 2006, 12(8): 939-944.
[29] Yang EV, Sood AK, Chen M, et al.Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells[J]. Cancer Res, 2006, 66(21): 10357-10364.
[30] Sood AK, Bhatty R, Kamat AA, et al.Stress hormone-mediated invasion of ovarian cancer cells[J]. Clin Cancer Res, 2006, 12(2): 369-375.

口服普萘洛尔对增殖期血管瘤患儿尿液bFGF、MMP-2和MMP-9表达水平的影响

Effects of oral propranolol on urine bFGF, MMP-2, MMP-9 expression in children with proliferative infantile hemangioma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

[1]	郑家伟, 王绪凯, 江成鸿, 秦中平, 范新东, 李凯, 杨耀武, 霍然, 刘少华, 赵吉宏, 汪小勇, 周德凯, 雷少榕. 外用马来酸噻吗洛尔治疗婴幼儿血管瘤中国专家共识[J]. 上海口腔医学, 2016, 25(6): 744-747.
[2]	郑家伟, 王绪凯, 秦中平, 范新东, 李凯, 杨耀武, 霍然, 刘少华, 赵吉宏, 汪小勇, 周德凯. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识[J]. 上海口腔医学, 2016, 25(3): 257-260.
[3]	郑善川，张玉茹，骆树瑜. GDNF对唾液腺腺样囊性癌嗜神经侵袭中基质降解和黏附能力的影响[J]. 上海口腔医学, 2016, 25(2): 212-216.
[4]	邰茂众，刘学键，秦中平，葛春晓，李克雷，陈涛. 婴幼儿血管瘤口服普萘洛尔治疗后的进一步处理[J]. 上海口腔医学, 2015, 24(6): 716-720.
[5]	郑家伟, 张凌, 陈正岗. 脉管异常的ISSVA新分类[J]. 上海口腔医学, 2015, 24(5): 385-388.
[6]	王智明,叶明,张雨霏,杨东升,马颖,周卓,张力平,刘维贤. 盘状结构域受体1与基质金属蛋白酶2在唾液腺腺样囊性癌中的表达及意义[J]. 上海口腔医学, 2015, 24(3): 326-330.
[7]	赵征, 刘洪臣, 黄征难, 鄂玲玲, 杨海青. 不同因子对大鼠牙源性间充质细胞成牙本质分化的影响[J]. 上海口腔医学, 2014, 23(6): 661-668.